Xolair Shortage Update: What Patients Need to Know in 2026

Xolair in 2026: What's the Current Situation?

If you rely on Xolair (Omalizumab) for asthma, chronic hives, nasal polyps, or food allergy, you've probably dealt with at least one frustrating moment over the past couple of years when your pharmacy couldn't fill your prescription. The Xolair supply situation has been one of the more challenging medication access stories in recent memory.

So where do things stand in 2026? Is Xolair still hard to get? What's changed? And what should you be doing right now to protect your access to treatment? This article breaks it all down.

Is Xolair Still in Shortage?

The short answer: it depends on where you are and which dose you need.

Xolair supply has improved compared to the acute shortages seen in late 2023 and throughout 2024, but the situation isn't fully resolved. Some doses and formulations remain intermittently constrained, and availability can vary significantly by region and pharmacy.

The biggest factor driving the ongoing tightness is simple: demand still exceeds pre-2024 projections. The February 2024 FDA approval of Xolair for IgE-mediated food allergy opened the medication up to millions of new patients, and the system is still adjusting.

Additionally, the FDA-approved biosimilar Omlyclo (Omalizumab-igec) is gradually entering the market, which is helping to relieve pressure — but biosimilar adoption takes time as insurers update formularies and prescribers gain comfort with the product.

Why Has Xolair Been Hard to Find?

Several factors have contributed to the Xolair shortage:

Demand Surge From the Food Allergy Indication

An estimated 33 million Americans have food allergies, and Xolair became the first FDA-approved treatment to reduce the risk of allergic reactions from accidental exposure. This single approval expanded the eligible patient population dramatically.

Biologic Manufacturing Complexity

Xolair is a monoclonal antibody produced from living cells in bioreactors. The manufacturing process takes months and involves extensive quality control. Scaling up production isn't as simple as running an extra batch — it requires validated facilities, regulatory approvals, and time.

Specialty Distribution Constraints

Xolair requires refrigeration and is only available through specialty pharmacies or doctor's offices. This narrow distribution channel means that when supply is tight, patients have fewer places to look.

Prior Authorization and Insurance Delays

Even when Xolair is physically available, insurance barriers can create their own delays. Prior authorization requests, step therapy requirements, and specialty pharmacy mandates can add days or weeks to the process.

For a deeper dive into these factors, see Why Is Xolair So Hard to Find?

How Much Does Xolair Cost in 2026?

Xolair remains one of the more expensive medications on the market:

• Cash price: $1,500 to $4,000+ per injection, depending on dose
• Annual cost: $30,000 to $50,000+ for patients receiving injections every 2 to 4 weeks
• With insurance: Copays vary widely. With commercial insurance and the manufacturer's co-pay program, some patients pay as little as $0 out-of-pocket per dose.
• Biosimilar (Omlyclo): Expected to be 15% to 30% less than brand-name Xolair, though exact pricing is still emerging.

If cost is a concern, our detailed guide covers all the ways to save: How to Save Money on Xolair in 2026.

New Options in 2026

The Omlyclo Biosimilar

The biggest development for Xolair access is the FDA-approved biosimilar Omlyclo (Omalizumab-igec) from Mylan/Viatris. A biosimilar is essentially the biologic equivalent of a generic — it works the same way, is equally safe, and meets the same FDA standards.

As insurers add Omlyclo to their formularies and more pharmacies begin stocking it, this should meaningfully improve supply and potentially lower costs. Ask your doctor if the biosimilar is an option for you.

Self-Injection at Home

Xolair is available in prefilled syringes and autoinjectors that allow trained patients to self-inject at home. This reduces dependency on doctor's office supply and gives you more flexibility in sourcing the medication through different specialty pharmacies.

Alternative Biologics

If Xolair remains difficult to access for your condition, alternative biologics like Dupixent, Nucala, Fasenra, or Tezspire may be appropriate depending on your diagnosis. See Alternatives to Xolair for a full comparison.

How to Find Xolair in Stock Right Now

Here's what we recommend:

1. Check Medfinder for real-time pharmacy availability near your location.
2. Start refills early — at least 2 to 3 weeks before your next dose is due.
3. Ask your doctor about in-office administration if your specialty pharmacy is out of stock.
4. Contact Genentech's Support for You program for help locating supply and navigating insurance.
5. Ask about the biosimilar Omlyclo — it may be more readily available.

For a complete walkthrough, read How to Find Xolair in Stock Near You.

Final Thoughts

The Xolair shortage has been a difficult reality for patients managing serious allergic conditions. While 2026 is better than 2024 in terms of supply, we're not entirely out of the woods. The biosimilar rollout and continued manufacturing expansion are positive signs, but patients should still be proactive about sourcing their medication.

Use tools like Medfinder, communicate early with your doctor and pharmacy, explore the biosimilar option, and stay informed. Your health depends on consistent treatment, and with the right strategy, you can stay on track.

For more information about Xolair, explore our related guides:

• What Is Xolair? Uses, Dosage, and What You Need to Know
• Xolair Side Effects: What to Expect
• Xolair Drug Interactions: What to Avoid